Olivia Pagani
Istituto Oncologico della Svizzera Italiana
Ospedale S. Giovanni
Bellinzona
Switzerland
Name/email consistency: high
- Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Pagani, O., Sessa, C., Nolè, F., Munzone, E., Crivellari, D., Lombardi, D., Thürlimann, B., Hess, D., Graffeo, R., Ruggeri, M., Longhi, S., Goldhirsch, A. Ann. Oncol. (2005)
- Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Pagani, O., Gelber, S., Price, K., Zahrieh, D., Gelber, R., Simoncini, E., Castiglione-Gertsch, M., Coates, A.S., Goldhirsch, A. Ann. Oncol. (2004)
- Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Pagani, O., Sessa, C., Nolè, F., Crivellari, D., Lombardi, D., Thürlimann, B., Hess, D., Borner, M., Bauer, J., Martinelli, G., Graffeo, R., Zucchetti, M., D'Incalci, M., Goldhirsch, A. Ann. Oncol. (2000)
- Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Pagani, O., Sessa, C., Martinelli, G., Crivellari, D., Buonadonna, A., Thürlimann, B., Hess, D., Borner, M., Bauer, J., Zampino, G., Zimatore, M., Graffeo, R., Riva, A., Goldhirsch, A. Ann. Oncol. (1999)
